Key result
Long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia improved health-related quality of life scores from baseline for up to 5 years (P<0.05).
Why the study?
Does long-term eltrombopag improve health-related quality of life in adults with persistent/chronic immune thrombocytopenia?
Population
302 adults with persistent/chronic immune thrombocytopenia who completed a previous eltrombopag ITP trial
Design
Cohort
Follow-up
median 2.37 years
Authors
Loading...
Associated with sustained HRQoL gains in chronic ITP; leaves open need for randomized confirmation.
Cohort (n=302)
Open-label
Does long-term eltrombopag improve health-related quality of life in adults with persistent/chronic immune thrombocytopenia?
p-value: p=<0.05
Long-term eltrombopag treatment in adults with chronic immune thrombocytopenia is associated with sustained improvements in health-related quality of life, particularly in fatigue and physical function.
Khélif et al. (2018) conducted a cohort in persistent/chronic immune thrombocytopenia (cITP) (n=302). Eltrombopag was evaluated on Changes in patient-reported HRQoL over time and association between HRQoL and platelet response (p=<0.05). Long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia improved health-related quality of life scores from baseline for up to 5 years (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: